Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Results: Treatment + Endometrial Cancer (5 results)
Any advanced or metastatic solid tumor except ovarian or prostate
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.
Advanced solid tumors
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Advanced endometrial cancer
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.
Advanced solid tumors
Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations
This study will look at safety and affectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.
Solid tumors that are MSI-High and resistant to prior immunotherapy
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.